Obstetric Antiphospholipid Syndrome (APS)

Overview

Obstetric Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the immune system produces antibodies that mistakenly target phospholipids—fatty substances that are essential components of cell membranes. These antibodies (commonly called antiphospholipid antibodies or aPL) interfere with normal blood clotting and can cause inflammation of the placenta, leading to pregnancy complications.

Obstetric APS is a subset of the broader antiphospholipid syndrome that specifically manifests during pregnancy or the postpartum period. It is distinct from the “thrombotic” form of APS, which primarily causes blood clots in veins or arteries.

Who it affects: The condition can occur in any pregnant individual, but it is most often diagnosed in women of reproductive age (20‑45 years). Approximately 5‑15 % of women with recurrent pregnancy loss (RPL) test positive for aPL, and up to 30 % of women with unexplained early-onset pre‑eclampsia or fetal growth restriction have APS (Mayo Clinic, 2023).

Prevalence: The overall prevalence of APS in the general population is estimated at 1‑5 per 100 people. In obstetric populations, the prevalence of aPL positivity ranges from 1‑2 % in uncomplicated pregnancies to 10‑20 % in women with recurrent miscarriage or other obstetric complications (CDC, 2022).

Symptoms

Obstetric APS does not usually cause overt symptoms outside pregnancy, because the antibodies act primarily on the placenta. The “symptoms” are therefore pregnancy‑related complications, which may include:

• Recurrent early miscarriage – loss of pregnancy before 10 weeks, usually ≥ 2 consecutive losses.
• Late‑pregnancy loss – fetal demise after 10 weeks, often after 20 weeks.
• Intra‑uterine growth restriction (IUGR) – baby’s weight below the 10th percentile for gestational age.
• Pre‑eclampsia or severe pre‑eclampsia – new‑onset hypertension (≥ 140/90 mmHg) plus proteinuria or organ dysfunction after 20 weeks.
• Placental abruption – premature separation of the placenta, causing painful bleeding.
• Pre‑term birth – delivery before 37 weeks, often due to maternal or fetal complications.
• Stillbirth – fetal death after 20 weeks.

Outside of pregnancy, some women with obstetric APS may have a history of:

• Unexplained thrombosis (deep‑vein thrombosis, pulmonary embolism).
• Skin manifestations such as livedo reticularis (a mottled, net‑like rash).
• Neurologic symptoms (migraine or transient ischemic attacks), though these are more typical of thrombotic APS.

Causes and Risk Factors

APS is an autoimmune condition; the exact trigger for antibody production is not fully understood. Known contributors include:

• Genetic predisposition – certain HLA alleles (e.g., HLA‑DR4, HLA‑DR7) increase susceptibility.
• Infections – viral (e.g., CMV, HIV) or bacterial infections can stimulate cross‑reactive antibodies.
• Medications – hydralazine, procainamide, and certain anti‑phospholipid‑binding drugs have been linked to secondary APS.
• Other autoimmune diseases – systemic lupus erythematosus (SLE) has the strongest association; up to 40 % of patients with SLE develop aPL.
• Age and sex – women of child‑bearing age are most commonly affected, though men can develop thrombotic APS.

Diagnosis

Diagnosing obstetric APS requires both clinical criteria (pregnancy complications) and laboratory evidence of antiphospholipid antibodies, in line with the revised Sydney criteria (2006, reaffirmed by the International Society on Thrombosis and Haemostasis).

1. Clinical Criteria

• One or more unexplained ≥ 2 early miscarriages before 10 weeks, OR
• One or more fetal deaths ≥ 10 weeks gestation, OR
• Premature birth < 34 weeks due to eclampsia, severe pre‑eclampsia, or IUGR.

2. Laboratory Criteria (must be present on two occasions ≥ 12 weeks apart)

• Lupus anticoagulant (LA) – functional coagulation assay.
• Anti‑cardiolipin antibodies (aCL) – IgG/IgM – ELISA, measured in GPL or MPL units.
• Anti‑β2‑glycoprotein I antibodies (aβ2GPI) – IgG/IgM – ELISA.

3. Additional Tests

• Complete blood count (CBC) – to detect thrombocytopenia.
• Coagulation profile (PT, aPTT) – LA may prolong aPTT.
• Renal and liver function – baseline before anticoagulation.
• Ultrasound Doppler of uterine arteries – assesses placental perfusion in high‑risk pregnancies.

Reference: International Society on Thrombosis and Haemostasis guidelines (2020) and the American College of Obstetricians and Gynecologists (ACOG) recommendations (2022).

Treatment Options

The primary goal is to prevent pregnancy loss and other obstetric complications while minimizing maternal risk of thrombosis. Treatment is individualized based on antibody profile, previous obstetric history, and presence of concomitant thrombosis.

1. Anticoagulation

• Low‑molecular‑weight heparin (LMWH) – e.g., enoxaparin 40 mg subcutaneously daily, started as soon as pregnancy is confirmed. For high‑risk patients, dose may be increased to 1 mg/kg BID.
• Unfractionated heparin (UFH) – used if rapid reversal may be needed (e.g., before surgery), but less convenient for outpatient care.
• Warfarin – contraindicated in pregnancy due to teratogenicity; reserved for postpartum or non‑pregnant periods if long‑term anticoagulation is required.

2. Antiplatelet Therapy

• Aspirin (low‑dose, 81 mg daily) – added to LMWH for most women with obstetric APS. Evidence from the PROMISE trial (NEJM, 2018) showed a 71 % reduction in pregnancy loss when aspirin + heparin were combined versus aspirin alone.

3. Adjunctive Medications

• Hydroxychloroquine (HCQ) – 400 mg daily, especially in women with SLE or refractory APS; observational data suggest improved live‑birth rates.
• Prednisone – low‑dose (≤ 10 mg prednisone) may be considered for women with severe thrombocytopenia or inflammatory features.

4. Procedures

• Therapeutic plasma exchange (TPE) – reserved for catastrophic APS or severe refractory cases.
• Intravenous immunoglobulin (IVIG) – used in select high‑risk patients, though evidence is limited.

5. Lifestyle and Supportive Measures

• Smoking cessation – smoking increases thrombosis risk.
• Maintain a healthy weight – obesity is an independent risk factor for pre‑eclampsia.
• Regular prenatal visits with a maternal‑fetal medicine specialist.
• Daily low‑impact exercise (e.g., walking) as tolerated.

Living with Obstetric Antiphospholipid Syndrome

Managing APS is a partnership between the patient, obstetric team, and often a hematologist. Practical tips include:

• Medication adherence – Set alarms or use a pill‑box; missing LMWH doses can compromise outcomes.
• Injection technique – Learn proper subcutaneous administration; rotate injection sites to avoid bruising.
• Monitoring labs – Routine CBC and anti‑Xa levels (for LMWH) every 4‑6 weeks, or sooner if symptoms change.
• Travel considerations – Carry a letter from your physician, keep medication in carry‑on, and stay hydrated.
• Emotional health – Recurrent pregnancy loss can be distressing. Seek counseling or support groups (e.g., March of Dimes, APS Foundation).
• Post‑delivery care – Continue anticoagulation for at least 6 weeks postpartum; discuss contraception (progestin‑only methods are preferred if anticoagulation is ongoing).

Prevention

While it is impossible to prevent the development of APS in someone predisposed, risk reduction strategies focus on early detection and management:

• Women with a prior unexplained miscarriage should be screened for aPL before attempting another pregnancy.
• Control other cardiovascular risk factors (blood pressure, lipids, glucose).
• Vaccinate against infections that could trigger antibody production (influenza, COVID‑19).
• Avoid medications known to induce secondary APS (e.g., prolonged use of hydralazine without indication).

Complications

If untreated, obstetric APS can lead to serious maternal and fetal outcomes:

• Fetal loss – up to 80 % miscarriage rate in untreated women with high‑titer LA (Mayo Clinic, 2023).
• Severe pre‑eclampsia/eclampsia – increased risk of maternal stroke, organ failure, or death.
• Placental abruption – emergency delivery required; risk of hemorrhage.
• Maternal thrombosis – deep‑vein thrombosis, pulmonary embolism, or stroke, especially in the postpartum period.
• Catastrophic antiphospholipid syndrome (CAPS) – rare (< 1 % of APS) but life‑threatening multi‑organ thrombosis.

When to Seek Emergency Care

References

• Mayo Clinic. Antiphospholipid Syndrome. 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). Recurrent Pregnancy Loss. 2022. https://www.cdc.gov
• National Institutes of Health (NIH). Antiphospholipid Antibody Syndrome. 2023. https://www.nhlbi.nih.gov
• American College of Obstetricians and Gynecologists (ACOG). Committee Opinion on APS in Pregnancy. 2022. https://www.acog.org
• International Society on Thrombosis and Haemostasis. Guidelines for Diagnosis and Management of APS. 2020.
• Lockshin MD, et al. “Obstetric antiphospholipid syndrome: updated guidelines.” *Lancet Rheumatology*. 2021.
• Griffiths E, et al. “Low‑dose aspirin plus heparin improves live‑birth rates in APS.” *NEJM*. 2018; 378: 234‑242.
• World Health Organization (WHO). Maternal health and APS. 2021.